Fig. 4: MUC1-C induces the MYCL, pluripotency, and NE lineage dictating TFs in MCC cells.
From: Addiction of Merkel cell carcinoma to MUC1-C identifies a potential new target for treatment
A Lysates from WaGa/tet-MUC1shRNA, MKL-1/tet-MUC1shRNA, and MCC26/tet-MUC1shRNA cells treated with vehicle or DOX for 4, 6, and 6 days, respectively, were immunoblotted with antibodies against the indicated proteins. B Scatter plot of the correlation between MUC1 and MYCL expression in MCC tumors. C Nuclear lysates from WaGa cells were precipitated with anti-MUC1-C and a control IgG. Input lysate and the precipitates were immunoblotted with antibodies against the indicated proteins. D GST and GST-MUC1-CD(FL; 1–72 aa) were incubated with purified full-length MYCL(1–364). The adsorbates and input were immunoblotted with anti-MYCL. Input of the GST proteins was assessed by Coomassie blue staining. E Venn diagram of common upregulated and downregulated genes in MKL-1/tet-MUC1shRNA and MKL-1/tet-MYCLshRNA cells treated with DOX for 5 days. F, G Lysates from WaGa/tet-MUC1shRNA (left) and MKL-1/tet-MUC1shRNA (right) cells treated with vehicle or DOX for 4 and 6 days, respectively, days were immunoblotted with antibodies against the indicated proteins. H Scatter plot of the correlation between MUC1 and ATOH1 expression in MCC tumors.
